Is there a role for surgery in metastatic colorectal cancer?

Slides:



Advertisements
Similar presentations
Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
Advertisements

Multiplication and Division
Akshra Verma, MD, MS Dr. Sohail A. Chaudhry MD
Update on Ovarian Cancer
St. John Providence Health System
Adding Up In Chunks.
ALOK SINHA Department of Medicine Manipal College of Medical Sciences Pokhara, Nepal.
Treatment.
Diagnosis.
Cancer of Unknown Primary
IN THE NAME OF GOD. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy The American Journal.
Dr. Carles Pericay Pijaume
Oncologic Results of Laparoscopic Versus Conventional Open Surgery for Stage II or III Left-Sided Colon Cancers A Randomized Controlled Trial A randomized.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Interventional Oncology Michael Kotton MD October 27, 2012.
DEBATE: What is the Optimal Strategy for Liver Only Metastatic Colon Cancer? Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center.
Total en bloc Spondylectomy If not for primary malignant tumors, for what else then? Sohail Bajammal, MBChB, MSc, FRCS(C) October 29, 2008.
Journal Meeting 時間 : AM 07:30 日期 : 06/29/2007 地點 : 胸腔外科辦公室 報告人 : R2 許博順.
Radiofrequency Ablation of Lung Cancer
Management of Colorectal Liver Metastasis
Surgical Management of Malignant Colonic Obstruction
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Liver Metastases Jean-Bernard Poulard MD, MBA, FACS Mount Sinai School of Medicine Queens Hospital Center Jamaica, NY.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Dr SH Chok Department of Surgery Ruttonjee & Tang Shiu Kin Hospitals
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
Resection For Lung Metastases M62 Coloproctology Course.
In the name of God Isfahan medical school Shahnaz Aram MD.
Nicolae Bacalbasa “Carol Davila” University Of Medicine and Pharmacy.
Treatment strategies for colon cancer at TNM stage IV Gunnar Arbman Department of Surgery Norrköping, Sweden Bergen June 2011.
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment.
Colonic stenting for intestinal obstruction due to left colon and rectal cancer Dr Sherman Lam TKOH JHSGR 26 April 2014.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Surgery of colorectal liver metastasis
“INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia.
HCC Guidelines
Pancreatic cancer.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal cancer: case report and literature review Alexandra.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Campbell’s & Literature review. Campbell 9 th & 10 th edition Cytoreductive nephrectomy  Palliation for: 1. Severe bleeding. 2. Pain. 3. Paraneoplastic.
Liver Cancer  A leading cause of death in the world  Can be primary or a metastatic site  Seen more in other parts of the world  incidence African.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Operative Management of Osteosarcoma Patients with Pulmonary Metastasis Jen Kramer, MD R2 Swedish Medical Center February 2011.
Eun Sun Jang, M.D., Ph.D Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine Diseases.
Debulking in Ovarian Cancer Ashraf Fawzy Nabhan Assistant Prof. of Obstetrics & Gynecology Ain Shams University, Cairo, Egypt.
Treatment of Colorectal Cancer Metastases to the Liver David U. Kim, MD University of Wisconsin School of Medicine and Public Health Department of Radiology.
Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.
Short-term outcome of neo-adjuvant chemotherapy
Intraoperative US of the Liver: Techniques and Clinical Applications
Percutaneous Cryoablation of Metastatic Ovarian Cancer for Local Tumor Control: Improved Patient Survival and Estimated Cost-Effectiveness Brandt P. Currier.
Pancreatic Cancer What you need to know to be able to educate your patients and their families.
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Retrospective Review of Efficacy of Radiofrequency Ablation for Treatment of Colorectal Cancer Liver Metastases From a Canadian Perspective  Benjamin.
Long-Term Outcomes After Surgical Resection of Pulmonary Metastases From Colorectal Cancer  Hisashi Suzuki, MD, PhD, Moriyuki Kiyoshima, MD, Miyuki Kitahara,
The role of simultaneous resection of synchronous liver metastasis and primary colorectal cancer Samuel Lo Department of Surgery.
Pulmonary Resection for Metastases from Colorectal Cancer
James D Luketich, Michael E Burt  The Annals of Thoracic Surgery 
Prognosis of angiosarcoma at different anatomic sites
The Development of an International Registry
General strategies of Cancer Treatment and evaluation of Response
Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma  Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas.
Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006  Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.
Presentation transcript:

Is there a role for surgery in metastatic colorectal cancer? Alan E. Harzman, MD Assistant Professor - Clinical Set B1 – Title Slide

Yes. Large Projection – Content Slide Thank you for your time.

Outline Obstruction Overview of colorectal metastasis Solid organ metastasis Peritoneal metastasis Set B1 – Content Slide

Obstruction Large Projection – Content Slide

Obstruction 8-29% of CRC patients at initial presentation 77% left-sided, 23% right-sided Set B1 – Content Slide

Interventions Low-residue diet and start chemotherapy or radiation Laser therapy to open lumen (for distal lesions) Fulguration Stent Diverting stoma Resection +/- anastomosis But not above another lesion Set B1 – Content Slide

Overview Large Projection – Content Slide

Sites of Colorectal Metastasis Peritoneum Liver Portal circulation Lung Ovary Bone Brain Incisions Spleen Other Set B1 – Content Slide

Sites of Possible Ectomies Peritoneum Liver Lung Ovary Bone Brain Incisions Spleen Other Set B1 – Content Slide

Basic Elements of a Good Metastasectomy Long disease-free interval Slow-growing disease Good functional status Good exit strategy This is not like a war. We can’t raise health like the government can raise taxes Set B1 – Content Slide

Lung as an example Large Projection – Content Slide

Factors in Lung Resection Ideally, a solitary metastasis. Possibly multiple nodules in one lung, or a single nodule in each. Primary site is controlled No other evidence of metastasis Patient can tolerate resection Set B1 – Content Slide

Survival After Lung Resection Operative mortality – 3% 3-year survival – 45-78% 5-year survival – consistently around 30% Set B1 – Content Slide

Liver Large Projection – Content Slide

Liver Metastasis 60% of the 150,000 new US cases of CRC yearly will eventually develop liver metastasis. 10% of those people will be candidates for curative-intent hepatic surgery 5-10 month survival untreated 24-23% 3-year and 2-8% 5-year survival of people who might have been surgical candidates in retrospect Set B1 – Content Slide

Surgical Options for Hepatic Metastasis Hepatectomy Hepatic Artery Infusion Radio frequency ablation Cryoablation Set B1 – Content Slide

Hepatectomy Mortality – 5% or less Morbidity – 20-50% 5-year survival – 25-40% 10-year survival – 20-26% Median survival 24-46 months Set B1 – Content Slide

Hepatectomy Not for Two-thirds will recur Extra-hepatic disease Except maybe pulmonary or anastomotic Incomplete resectability Two-thirds will recur Set B1 – Content Slide

aka peritoneal carcinomatosis Peritoneum aka peritoneal carcinomatosis Large Projection – Content Slide

'Omental cake' in a patient with peritoneal carcinomatosis arising from appendiceal cancer. Glockzin et al. World Journal of Surgical Oncology 2009 7:5   doi:10.1186/1477-7819-7-5

Peritoneal Carcinomatosis - Mechanisms Seeding from T4 CRC Extravasation with perforation of the tumor Tumor perforation at operation Leakage of tumor cells from lymphatics or veins at time of operation Set B1 – Content Slide

Peritoneal Carcinomatosis 10-15% of patients at CRC presentation 25-35% of CRC recurrences Survival 6-8 months without therapy Can lead to malignant ascites or malignant bowel obstruction Set B1 – Content Slide

Peritoneal Surface Malignancy Group Increased probability of complete macroscopic cytoreduction in CRC ECOG performance status <=2 No extra-abdominal disease Up to three, small, resectable hepatic mets No biliary obstruction No ureteral obstruction Small bowel – no gross mesenteric disease Small-volume disease in gastro-hepatic ligament Set B1 – Content Slide

(Cotte et al., 2009)

Pseudomyxoma Peritonei Often diagnosed with acute appendicitis, abdominal swelling or ovarian mass Minimal operating should be done at the time of diagnosis Confusing pathology Set B1 – Content Slide 25

Factors in Pseudomyxoma Peritonei Tumor grade Extent of mesenteric invasion Liver metastasis Age Set B1 – Content Slide

Cytoreductive Surgery Peritonectomy (parietal and visceral) Greater omentectomy Lesser omentectomy Splenectomy Cholecystectomy Liver capsule resection Small bowel resection Large bowel/rectal resection Hysterectomy Oopherectomy Cystectomy Omphalectomy – for invasion of umbilicus Set B1 – Content Slide

Omphalectomy in a patient with umbilical tumor infiltration. Glockzin et al. World Journal of Surgical Oncology 2009 7:5   doi:10.1186/1477-7819-7-5

(Cotte et al., 2009)

(Cotte et al., 2009)

Intraperitoneal Chemotherapy Mortality – 5% Morbidity – 35% Various agents, especially mitomycin C Hyperthermia Increased chemotherapeutic activity Direct effects – protein denaturation, induction of apoptosis, inhibition of angiogenesis High local dose with less systemic toxicity Complete gross resection is most important 5-year survival – 27-54% Set B1 – Content Slide

Schematic diagram of HIPEC procedure. Glockzin et al. World Journal of Surgical Oncology 2009 7:5   doi:10.1186/1477-7819-7-5

Cytoreductive Surgery and IPHP Morbidity 25-41% Surgical – Anastomotic leak, ileus, wound infection, bleeding, thrombosis, embolism Chemotherapeutic – Leukopenia, anemia, thrombopenia, heart, liver, renal Mortality 0-8% Shows individual and institutional learning curves Set B1 – Content Slide

Survival With cytoreductive surgery and intraperitoneal hyperthermic chemotherapy Survival 15-32 months 28-60 months with complete macroscopic cytoreduction With systemic chemotherapy alone (5-FU/leucovorin) 12-14 months Set B1 – Content Slide 34

Quality of Life Acceptable functional status returns at 3-6 months 32% depressed at surgery, and 24% one year afterward Role and social functioning may remain impaired in long-term functioning Set B1 – Content Slide 35

Summary There are a wide variety of options for surgical therapy in metastatic colorectal cancer. Most are very invasive and somewhat risky. However, they all extend meaningful life in properly selected patients. Those patients may be the minority of patients with metastatic colorectal cancer, but with 150,000 new cases a year, there are many of them out there. Set B1 – Content Slide 36

References Berri, RN, & Abdalla EK. (2009). Curable metastatic colorectal cancer: recommended paradigms. Current Oncology Reports, 11, 200-208. Cotte, E, Passot, G, Mohamed, F, Vaudoyer, D, & Glehen, O. (2009). Management of peritoneal carcinomatosis from colorectal cancer. The Cancer Journal, 15(3), 243-248. Glockzin, G. (2009). Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Surgical Oncology, 7(5). Gordon, PH, & Nivatvongs, S. (2007). Principles and practice of surgery for the colon, rectum, and anus. Third edition. New York: Informa Healthcare. Moran, B, Baratti, D, Yan, TD, Kusamura, S, & Deraco, M. (2008). Consensus statement on teh loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). Journal of Surgical Oncology, 98, 277-282. Wolff, BG, Fleshman, JW, Beck, DE, Pemberton, JH, & Wexner, SD. (2007). The ASCRS textbook of colon and rectal surgery. New York: Springer. Set B1 – Content Slide

Large Projection Closing Slide